SCIENTIFIC REPORT 2004 - Sylvester Comprehensive Cancer Center

P U B L I C A T I O N S 2 0 0 2 - 2 0 0 3
Deutscher, MP . Degradation of stable RNA in
bacteria. Journal of Biological Chemistry
278:45041-44, 2003.
Hudder, A, Nathanson, L, and Deutscher, MP .
Organization of mammalian cytoplasm. Molecular
and Cellular Biology 23:9318-26, 2003.
Feun, LG, Modiano, M, Lee, K, Mao, J, Marini,
A, Savaraj, N, Plezia, P, Almassian, B, Colacino,
E, Fischer, J, and MacDonald, S. Phase I and
pharmacokinetic study of 3-aminopyridine-2-
carboxaldehyde thiosemicarbazone (3-AP) using a
single intravenous dose schedule. Cancer Chemotherapy
and Pharmacology 50:223-29, 2002.
Wangpaichitr, M, Landy, H, Wu, CJ, Feun, LG,
Xu, R, Xu, J, and Savaraj, N. Procollagen-like
protein as a molecular target in the treatment of
primary brain tumor. ScientificWorld Journal
2:125-26, 2002.
Feun, LG, Savaraj, N, Hurley, J, and Marini, A.
Phase II trial of Paclitaxel and Dacarbazine with
filgrastim administration in advanced malignant
melanoma. Cancer Investigation 20:357-61,
2002.
Agarwala, SS, Glaspy, J, O’Day, SJ, Mitchell, M,
Gutheil, J, Whitman, E, Gonzalez, R, Hersh, E,
Feun, LG, Belt, R, Meyskens, F, Hellstrand, K,
Wood, D, Kirkwood, JM, Gehlsen, KR, and
Naredi, P. Results from a randomized phase III
study comparing combined treatment with histamine
dihydrochloride plus interleukin-2 versus
interleukin-2 alone in patients with metastatic
melanoma. Journal of Clinical Oncology 20:125-
33, 2002.
Feun, LG, O’Brien, C, Molina, E, Rodriguez, M,
Jeffers, L, Schiff, ER, Marini, A, Savaraj, N, and
Ardalan, B. Recombinant leukocyte interferon,
doxorubicin, and 5FUDR in patients with hepatocellular
carcinoma-A phase II trial. Journal of
Cancer Research and Clinical Oncology 129:17-
20, 2003.
Prados, MD, Schold SC Jr., Fine, HA, Jaeckle, K,
Hochberg, F, Mechtler, L, Fetell, MR,
Phuphanich, S, Feun, LG, Janus, TJ, Ford, K,
and Graney, W. A randomized, double-blind, placebo-controlled,
phase 2 study of RMP-7 in
combination with carboplatin administered intravenously
for the treatment of recurrent malignant
glioma. Neuro-oncology 5:96-110, 2003.
Robles, C, Furst, AJ, Sriratana, P, Lai, S, Chua, L,
Donnelly, E, Solomon, J, Sundaram, M, Feun,
LG, and Savaraj, N. Phase II study of vinorelbine
with low dose prednisone in the treatment of
hormone-refractory metastatic prostate cancer.
Oncology Reports 10:885-89, 2003
Savaraj, N, Wu, C, Wangpaichitr, M, Kuo, MT,
Lampidis, T, Robles, C, Furst, AJ, and Feun, LG.
Overexpression of mutated MRP4 in cisplatin
resistant small cell lung cancer cell line: collateral
sensitivity to azidothymidine. International Journal
of Clinical Oncology 23:173-79, 2003
Dewailly, E, Furgal, C, Knap, A, Galvin, J,
Baden, D, Bowen, B, Depledge, M, Dugua, L,
Fleming, LE, Ford, T, Moser, F, Owen, R, Suk,
WA, and Unluata, U. Indicators of ocean and
human health. Cancer Journal of Public Health
93: S34-8, 2002.
Grant, P, Skinner, HG, Fleming, LE, and Bean,
JA. Influence of structured encounter forms on
documentation by community pediatricians.
Southern Medical Journal 95:1026-31, 2002.
Knap, A, Dewailly, E, Furgal, C, Galvin, J,
Baden, D, Bowen, RE, Depledge, M, Duguay, L,
Fleming, LE, Ford, T, Moser, F, Owen, R, Suk,
WA, and Unluata, U. Indicators of ocean health
and human health: developing a research and
monitoring framework. Environmental Health
Perspectives 110:839-45, 2002.
Zhou, O, Shimoda, H, Gao, B, Oh, S, Fleming,
LE, and Yue, G. Materials science of carbon
nanotubes: fabrication, integration, and properties
of macroscopic structures of carbon
nanotubes. Accounts of Chemical Research
35:1045-53, 2002.
162
UM/Sylvester Comprehensive Cancer Center Scientific Report 2004